SG10201509397SA - Cells for producing recombinant iduronate-2-sulfatase - Google Patents

Cells for producing recombinant iduronate-2-sulfatase

Info

Publication number
SG10201509397SA
SG10201509397SA SG10201509397SA SG10201509397SA SG10201509397SA SG 10201509397S A SG10201509397S A SG 10201509397SA SG 10201509397S A SG10201509397S A SG 10201509397SA SG 10201509397S A SG10201509397S A SG 10201509397SA SG 10201509397S A SG10201509397S A SG 10201509397SA
Authority
SG
Singapore
Prior art keywords
sulfatase
cells
producing recombinant
recombinant iduronate
iduronate
Prior art date
Application number
SG10201509397SA
Other languages
English (en)
Inventor
Ferenc Boldog
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of SG10201509397SA publication Critical patent/SG10201509397SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG10201509397SA 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase SG10201509397SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
SG10201509397SA true SG10201509397SA (en) 2015-12-30

Family

ID=49778522

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408702VA SG11201408702VA (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase
SG10201509397SA SG10201509397SA (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201408702VA SG11201408702VA (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Country Status (27)

Country Link
US (3) US9150841B2 (https=)
EP (1) EP2874649B1 (https=)
JP (3) JP6067849B2 (https=)
KR (1) KR101710487B1 (https=)
CN (2) CN107267460A (https=)
AU (3) AU2013282400B2 (https=)
BR (1) BR112014032560B1 (https=)
CA (1) CA2877521C (https=)
CL (1) CL2014003568A1 (https=)
CO (1) CO7240394A2 (https=)
CR (1) CR20140586A (https=)
DO (1) DOP2014000298A (https=)
EA (2) EA202090805A1 (https=)
ES (1) ES2718346T3 (https=)
GT (1) GT201400302A (https=)
HK (1) HK1209331A1 (https=)
IL (3) IL236343A (https=)
MX (2) MX336716B (https=)
MY (2) MY189314A (https=)
NZ (2) NZ734670A (https=)
PE (1) PE20150957A1 (https=)
PH (2) PH12016500011B1 (https=)
SG (2) SG11201408702VA (https=)
TR (1) TR201904435T4 (https=)
UA (1) UA118955C2 (https=)
WO (1) WO2014005019A2 (https=)
ZA (1) ZA201409396B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6473079B2 (ja) * 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN102665890B (zh) * 2009-10-09 2016-02-24 蓝立方知识产权公司 生产氯化和/或氟化丙烯和高级烯烃的绝热活塞流反应器及方法
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
GT201400302A (es) 2019-05-22
TR201904435T4 (tr) 2019-05-21
PH12016500011A1 (en) 2019-08-14
IL274266A (en) 2020-06-30
UA118955C2 (uk) 2019-04-10
EA201492183A1 (ru) 2015-06-30
IL236343A0 (en) 2015-02-26
WO2014005019A3 (en) 2014-02-27
EA035511B1 (ru) 2020-06-26
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
JP6302499B2 (ja) 2018-03-28
EA202090805A1 (ru) 2020-11-30
EP2874649A2 (en) 2015-05-27
EP2874649B1 (en) 2019-01-02
MX336716B (es) 2016-01-28
ZA201409396B (en) 2018-05-30
HK1209331A1 (en) 2016-04-01
US20180010108A1 (en) 2018-01-11
EP2874649A4 (en) 2016-05-04
CO7240394A2 (es) 2015-04-17
US20140004593A1 (en) 2014-01-02
MY189314A (en) 2022-02-04
CR20140586A (es) 2015-04-06
BR112014032560A2 (pt) 2018-03-06
CA2877521C (en) 2021-06-01
CA2877521A1 (en) 2014-01-03
AU2018200710A1 (en) 2018-02-22
PH12014502868B1 (en) 2015-02-23
BR112014032560B1 (pt) 2022-04-26
AU2016200460B2 (en) 2017-11-02
JP2015521848A (ja) 2015-08-03
CN107267460A (zh) 2017-10-20
HK1209651A1 (en) 2016-04-08
KR20150030242A (ko) 2015-03-19
US9150841B2 (en) 2015-10-06
WO2014005019A2 (en) 2014-01-03
JP6067849B2 (ja) 2017-01-25
CL2014003568A1 (es) 2015-04-24
US9719074B2 (en) 2017-08-01
AU2013282400A1 (en) 2015-01-29
AU2016200460A1 (en) 2016-02-18
US20160053238A1 (en) 2016-02-25
KR101710487B1 (ko) 2017-02-27
PH12014502868A1 (en) 2015-02-23
ES2718346T3 (es) 2019-07-01
DOP2014000298A (es) 2015-03-31
NZ734670A (en) 2019-12-20
IL254560A0 (en) 2017-11-30
JP6755272B2 (ja) 2020-09-16
AU2013282400B2 (en) 2016-02-04
JP2016105737A (ja) 2016-06-16
IL254560B (en) 2020-05-31
PE20150957A1 (es) 2015-07-15
MX2015000189A (es) 2015-04-08
PH12016500011B1 (en) 2022-07-15
NZ703137A (en) 2017-08-25
JP2018088933A (ja) 2018-06-14
IL274266B (en) 2021-04-29
CN104540517A (zh) 2015-04-22
MX366155B (es) 2019-06-28
AU2018200710B2 (en) 2019-11-14
IL236343A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
IL274266B (en) Cells for the production of recombinant iduronate-2-sulfatase
SG11201502216UA (en) Cell lines
ZA201503358B (en) Structure
IL238836A0 (en) User-based interactive elements
GB201319035D0 (en) Spolier structure
IL265867A (en) Amplifiers of production cell lines
GB2507735B (en) Fuel cell components
EP2835852A4 (en) FUEL CELL
EP2830130A4 (en) FUEL CELL
HUP1300640A2 (en) Belt-mounting structure
EP2882020A4 (en) FUEL CELL
GB201313231D0 (en) Fuel Cell Components
GB201220058D0 (en) Cell differentiation
EP2805544A4 (en) CELL HANDOVER
GB2507739B (en) Fuel cell components
EP2871919A4 (en) STRUCTURE
GB2500031B (en) Fuel cells
GB201104761D0 (en) Biodiesel production
EP2808929A4 (en) FUEL CELL
EP2804245A4 (en) FUEL CELL
GB201214618D0 (en) Double ended cell
TWM433497U (en) Structure for jacklight
GB201218496D0 (en) Cell
GB201222707D0 (en) Fuel cells
GB201119658D0 (en) Cell